---
document_datetime: 2025-12-10 15:02:33
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eydenzelt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: eydenzelt-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 16.5107733
conversion_datetime: 2025-12-20 08:34:15.560175
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Eydenzelt

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.I.a.2 Changes in the manufacturing | 05/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000297221                     | process of the active substance - B.I.a.2.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |             |                                                                                                                                                                                                                                                 |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000281997 | This was an application for a group of variations. B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.c Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - | 23/10/2025 | SmPC and PL | The SmPC section 4.4, 6.3, 6.4 has been updated as follows: Editorial change and update of Shelf life (pre-filled syringe) and storage conditions (pre- filled syringe/vial). The PL has been updated accordingly and with editorial amendment. |

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000258093   | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging   | 09/10/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                                       | manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/ immunological medicinal products, or for pharmaceutical forms manufactured by complex manufacturing processes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |                |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| Variation type II / EMA/VR/0000268004 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.b Substantial change to the manufacturing process of the active substance which may have a significant impact on the quality, safety or efficacy of the medicinal product - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted | 04/09/2025 | N/A | Not applicable |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000272942   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data. The PL is updated accordingly. The change follows assessment of the same change to the reference product, Eylea. Additionally, the MAH took the opportunity to implement editorial changes to the PI in EN and DE to align with the reference product PI. The PI in DE was further updated to add a missing word, and to align user instructions in section 6.6 of the SmPC and the PL with the EN PI of Eydenzelt. Furthermore, the MAH took the opportunity to revise the term \"plastic\" to \"COP\" for the Immediate Packaging nomenclature in Annex A, as   | 06/06/2025   | SmPC and PL   | To update section 4.8 of the SmPC in order to add 'scleritis' to the list of adverse drug reactions (ADRs) with a frequency of '0.2 cases per 1 million injections' based on pharmacovigilance data. The PL is updated accordingly. The change follows assessment of the same change to the reference product, Eylea.   |
|-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000266692   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/05/2025   | SmPC and PL   | To update section 2 and 4.4 of the SmPC, to align the information on excipients with the reference product Eylea, after assessment of the same change                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted                                                                                                                                   | for the reference product.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| C.I.2.a - To update section 2 and 4.4 of the SmPC, to align the information on excipients with the reference product Eylea, after assessment of the same change for the reference product. In addition, the MAH took the opportunity to update the local representative information for ES. Furthermore, the MAH took the opportunity |                              |
| to implement editorial changes to the DE                                                                                                                                                                                                                                                                                              |                              |
| SmPC and PL to align with the reference                                                                                                                                                                                                                                                                                               |                              |
| product and the QRD template.                                                                                                                                                                                                                                                                                                         |                              |